Shopping Cart
- Remove All
- Your shopping cart is currently empty
Biricodar is a P-glycoprotein and MRP-1 modulator.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,820 | 8-10 weeks | |
50 mg | $2,380 | 8-10 weeks | |
100 mg | $3,100 | 8-10 weeks |
Description | Biricodar is a P-glycoprotein and MRP-1 modulator. |
In vitro | Biricodar demonstrates activity against P-glycoprotein (Pgp) and MRP-1 by increasing drug uptake and retention, reversing drug resistance mediated by wild-type BCRP (BCRPR482), and enhancing uptake, retention, and cytotoxicity in HL60/Adr (MRP-1) and 8226/MR20 cells (BCRP(R482)), while having minimal effect on MCF7 AdVP3000 cells (BCRP(R482T))[1]. It effectively inhibits photoaffinity labeling of P-glycoprotein by [3H]azidopine or [125I]iodoaryl azido-prazosin, with EC50 values of 0.75 and 0.55 μM[3]. In 8226/Dox6 cells (Pgp), biricodar enhances mitoxantrone and daunorubicin uptake by 55% and 100%, respectively, retention by 100% and 60%, respectively, and cytotoxicity by 3.1- and 6.9-fold, respectively. VX-710, a non-macrocyclic pipecolinate derivative that binds the FK506 receptor protein, has been shown to restore sensitivity in a range of multidrug-resistant cells, including myeloma, melanoma, carcinoma, and leukemia[2]. |
Alias | VX-710 |
Molecular Weight | 603.71 |
Formula | C34H41N3O7 |
Cas No. | 159997-94-1 |
Relative Density. | 1.195 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.